Hebe dich für diese Rolle von der Masse ab — erstelle in etwa einer Minute einen maßgeschneiderten Lebenslauf und ein Anschreiben.
EPFL’s LBMM laboratory in Lausanne seeks a postdoctoral researcher with a focus on highly multiplexed single-cell RNAseq-based antibody discovery. The successful candidate will lead optimization of single-cell sequencing workflows, supervise FACS sorting, prepare libraries, analyze data, and collaborate with bioinformaticians in an interdisciplinary environment.
Experience in droplets/microfluidics is beneficial.
The lab of biomedical microfluidics (LBMM; www.epfl.ch/labs/lbmm) at the Swiss Federal Institute of Technology in Lausanne (EPFL), is looking for postdocs with a primary training in single-cell biology, next generation sequencing or antibody discovery. Experience in droplet-microfluidics, including use of commercial devices such as the 10X Genomics platform is beneficial, but not absolutely crucial. LBMM has already developed powerful technology platforms in the field of biomedicine and genomics over the past years, also leading to the establishment of two startup companies (www.veraxa.com and www.thera-me.ch). Having a comprehensive microfluidic toolbox at hand (and expanding it continuously), we are now inviting applications for highly multiplexed single-cell RNAseq-based antibody discovery. The idea behind this project is to exploit transcriptomic data sets for the discovery of new therapeutic antibodies. The lab has a very translational focus, running a tech development lab on the EPFL campus and a translational lab in the AGORA cancer research center (with direct access to patient material). Furthermore, a strong network of clinical partners in Europe and the US has been established. The successful candidate will closely interact with experts in microfluidics and bioinformatics, while spearheading the above project.
For any further information, please contact: Prof. Christoph Merten, christoph.merten@epfl.ch
Contract Start Date : 10/01/2026
Activity Rate : 100.00
Contract Type: CDD
Duration: 1 year, renewable
Reference: 2443